Yoav Lurie

Summary

Country: Israel

Publications

  1. ncbi Acute hepatitis C in Israel: a predominantly iatrogenic disease?
    Yoav Lurie
    Liver Disease Unit, Gastroenterology Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    J Gastroenterol Hepatol 22:158-64. 2007
  2. ncbi Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study
    Geert Bezemer
    Dpt, Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands
    BMC Gastroenterol 12:11. 2012
  3. ncbi Celiac disease diagnosed in the elderly
    Yoav Lurie
    Liver Disease Unit, Gastroenterology Institue, Tel Aviv Sorasky Medical Center, Tel Aviv, Israel
    J Clin Gastroenterol 42:59-61. 2008
  4. ncbi Medex test, a novel modality for liver disease diagnosis: a pilot study
    Yoav Lurie
    Liver Disease Unit, Gastroenterology Institute, Tel Aviv Sorasky Medical Center, Israel
    J Clin Gastroenterol 41:700-5. 2007
  5. ncbi A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease
    Shira Zelber-Sagi
    The Liver Unit, Department of Gastroenterology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Clin Gastroenterol Hepatol 4:639-44. 2006
  6. ncbi A secreted form of the asialoglycoprotein receptor, sH2a, as a novel potential noninvasive marker for liver fibrosis
    Elena Veselkin
    Department of Cell Research and Immunology, George Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
    PLoS ONE 6:e27210. 2011
  7. ncbi Role of CYP2D6 polymorphism in predicting liver fibrosis progression rate in Caucasian patients with chronic hepatitis C
    Sigal Fishman
    Liver Unit, Gastroenterology Institute, Tel Aviv Sourasky Medical Center, Affiliated to Sackler School of Medicine, Tel Aviv, Israel
    Liver Int 26:279-84. 2006
  8. ncbi HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project)
    Massimo Pilli
    Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    Gastroenterology 133:1132-43. 2007
  9. ncbi Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin
    Maria Buti
    Liver Unit, Hospital General Universitari Vall d Hebron, Barcelona, Spain
    Hepatology 35:930-6. 2002
  10. ncbi Dynamic transperineal ultrasound in the diagnosis of pelvic floor disorders: pilot study
    Marc Beer-Gabel
    Department of Gastroenterology, Kaplan Medical Center, Rehovot, Israel
    Dis Colon Rectum 45:239-45; discussion 245-8. 2002

Collaborators

  • Shira Zelber-Sagi
  • Guy Rosner
  • Sigal Fishman
  • Juan I Esteban
  • Martin Lagging
  • J M Pawlotsky
  • Maria Buti
  • S Zeuzem
  • Geert Bezemer
  • Elena Veselkin
  • Solko W Schalm
  • Avidan U Neumann
  • Carlo Ferrari
  • Francesco Negro
  • Massimo Pilli
  • Marc Beer-Gabel
  • Bettina E Hansen
  • Arthur R Van Gool
  • Elke Verheij-Hart
  • Robert J de Knegt
  • Shimon Reif
  • Lana Bar
  • Moshe Santo
  • Irma Elashvili
  • Maria Kondratyev
  • Efrat Ron
  • Gerardo Z Lederkremer
  • Christophe Hezode
  • Gabriele Missale
  • Amalia Penna
  • Alessandro Zerbini
  • Georgios Germanidis
  • Esther Lukasiewicz
  • Alessandra Orlandini
  • Yonit Homburger
  • Michael von Wagner
  • Bart L Haagmans
  • Naphtali Barzilai
  • Stephen Malnick
  • Andrew Zbar
  • David Bass
  • Mark Teshler

Detail Information

Publications10

  1. ncbi Acute hepatitis C in Israel: a predominantly iatrogenic disease?
    Yoav Lurie
    Liver Disease Unit, Gastroenterology Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    J Gastroenterol Hepatol 22:158-64. 2007
    ..The aim of this study was to examine transmission routes and clinical characteristics in a group of patients with acute hepatitis C in Israel...
  2. ncbi Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study
    Geert Bezemer
    Dpt, Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands
    BMC Gastroenterol 12:11. 2012
    ..HRQL improves after successful treatment. This trial explores the course of and factors associated with HRQL in patients given individualized or standard treatment based on early treatment response (Ditto-study)...
  3. ncbi Celiac disease diagnosed in the elderly
    Yoav Lurie
    Liver Disease Unit, Gastroenterology Institue, Tel Aviv Sorasky Medical Center, Tel Aviv, Israel
    J Clin Gastroenterol 42:59-61. 2008
    ..Nevertheless, CD is still underdiagnosed in elderly patients. In this study, we describe a case series of CD patients diagnosed after the age of 60...
  4. ncbi Medex test, a novel modality for liver disease diagnosis: a pilot study
    Yoav Lurie
    Liver Disease Unit, Gastroenterology Institute, Tel Aviv Sorasky Medical Center, Israel
    J Clin Gastroenterol 41:700-5. 2007
    ..This method is based on neuroreflexology, a branch of complementary medicine. This study addressed 2 questions: can Medex Test detect liver disease, and can it measure the severity of a known liver disease...
  5. ncbi A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease
    Shira Zelber-Sagi
    The Liver Unit, Department of Gastroenterology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Clin Gastroenterol Hepatol 4:639-44. 2006
    ..4%). There was a statistically significant reversal of fatty liver by US only in the orlistat group (P<.05). CONCLUSIONS: Orlistat improves serum ALT levels and steatosis on US in NAFLD patients, beyond its effect on weight reduction...
  6. ncbi A secreted form of the asialoglycoprotein receptor, sH2a, as a novel potential noninvasive marker for liver fibrosis
    Elena Veselkin
    Department of Cell Research and Immunology, George Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel
    PLoS ONE 6:e27210. 2011
    ..Here we determined and report that sH2a, present at constant levels in serum from healthy individuals is altered upon liver fibrosis, reflecting the status of hepatocyte function...
  7. ncbi Role of CYP2D6 polymorphism in predicting liver fibrosis progression rate in Caucasian patients with chronic hepatitis C
    Sigal Fishman
    Liver Unit, Gastroenterology Institute, Tel Aviv Sourasky Medical Center, Affiliated to Sackler School of Medicine, Tel Aviv, Israel
    Liver Int 26:279-84. 2006
    ..Previous studies have demonstrated that CYP2D6 polymorphism is associated with liver cirrhosis. The aim of the present study was to find out whether CYP2D6*4, the poor metabolizer allele can predict fibrosis progression rate...
  8. ncbi HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project)
    Massimo Pilli
    Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    Gastroenterology 133:1132-43. 2007
    ....
  9. ncbi Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin
    Maria Buti
    Liver Unit, Hospital General Universitari Vall d Hebron, Barcelona, Spain
    Hepatology 35:930-6. 2002
    ..Higher doses of peginterferon alfa-2b also accelerate viral clearance...
  10. ncbi Dynamic transperineal ultrasound in the diagnosis of pelvic floor disorders: pilot study
    Marc Beer-Gabel
    Department of Gastroenterology, Kaplan Medical Center, Rehovot, Israel
    Dis Colon Rectum 45:239-45; discussion 245-8. 2002
    ....